Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 20, 2013 (14 years ago)

Progesterone 50 mg/ml

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Progesterone 50 mg/ml, Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907

Drug: Progesterone

Recalling firm
Clinical Specialties Compounding Pharmacy
Origin
GA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-662-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Progesterone recalls

See all
Class II · Moderate risk

Endometrin

cGMP deviations: potential for Microbial Contamination of Non-Sterile Products

Terminated Microbial contamination Ferring Pharmaceuticals Inc NDC 55566-6500-03 D-0879-2023

Other recalls by Clinical Specialties Compounding Pharmacy

All 2013 recalls
Class II · Moderate risk

Vancomycin 50 mg/ml

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-680-2013
Class II · Moderate risk

Tetracaine

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-679-2013